WiseGuyRerports.com Presents “Glioma Diagnosis and Treatment Market Research Report – Forecast to 2023” New Document to its Studies Database
A Glioma is a type of brain tumor that is also known as a primary brain tumor. Numerous types of gliomas, including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma, are classified based on the cell type’s origin. About 33% of all tumors in the brain were gliomas. They come from glial cells that surround the brain’s neurons. More than 79,000 cases of new primary brain tumors were diagnosed in 2017. Out of these, 24.7 percent were positively identified as glioma cases.
The global Glioma Diagnosis and Treatment market is expected to grow at a Common Annual Growth Rate (CAGR) of approximately 10.1 percent over the next 6 years forecast period. Brain tumors are one of leading causes of cancer in children and adolescents. Glioma is the most common type of brain tumor comprising around half of all astrocytoma. The spike in the prevalence of glioblastoma over the years was responsible for the growth of the demand for diagnosis and treatment of glioma. Forthcoming product launches and scientific advances are instrumental in market growth. Therefore, over the forecast period, the current unmet needs are expected to drive the glioma industry.
The growing market for the management of symptoms associated with brain cancer, the growing incidence of brain cancer, and advances in the distribution of medications to brain cancer cells, are some of the main factors that increase competition in the global market for Glioma Diagnosis and Treatment. In addition, the introduction of new treatments coupled with different organizations raising knowledge and growing geriatric population are factors that drive the growth of the global market for diagnosis and treatment of glioma. Likewise, the advancement of drug delivery technology, a convergence of advanced testing techniques, and increased awareness of various types of brain tumors are driving this market’s expansion.
- Thermo Fisher Scientific Inc. (U.S.)
• Emcure Pharmaceuticals Ltd. (India)
• Sigma-Aldrich Co. (U.S.)
• Pfizer Inc. (U.S.)
• Taj Pharmaceuticals Limited (India)
• Novartis International AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• GE Healthcare (U.S.)
• Siemens Healthineers (U.S.)
• Philips Healthcare (U.S.)
• Shimadzu Corporation (Japan)
• Toshiba Medical Systems Corporation (Japan)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-Le Roche AG (Switzerland)
• Arbor Pharmaceuticals, LLC (U.S.)
• Sun Pharmaceutical Industries, Ltd. (India)
• Amneal Pharmaceuticals. LLC (U.S.)
• AstraZeneca (UK)
• Carestream Health (U.S.)
• Hitachi Medical Corporation (U.S.)
Form, diagnosis, procedure, class, place, and end-user, are the elements that segment the Glioma Diagnosis and Treatment market for America’s glioma. Geographically, the diagnosis and care demand for America’s glioma is split into two major regions, North America and South America. In fact, about 80,000 new cases linked to brain tumors are estimated to have been identified in 2017, including 26,000 major malignant brain tumors. The global market for diagnosis and treatment for glioma is made up of four major regions, the Americas, Europe, Asia Pacific, and the Middle-East and Africa.
Growing medical tourism and metastatic tumor prevalence needing surgical procedures promote market growth in the Middle-East and Africa. Due to the increasing prevalence of brain tumors in the Asia-Pacific countries like China and others, Asia Pacific is expected to be the most lucrative market
Glioma Diagnosis and Treatment. Growth in the Asian market is powered by the growing healthcare system and the emergence in this area of untapped market opportunities. Due to the increasing number of manufacturers combined with the increasing market saturation, this area is called a developing sector.
Scientists have also developed a new scanning method that can help completely eliminate malignant tumors from the human body. This form of MRI can help surgeons better identify the tumor. Scientists claimed that this technique involves using a synthetic version of a molecular compound present in a scorpion’s venom. The process also involves the use of an infrared (IR) lens as well as a tozuleristide (BLZ-100) scanning reagent. This method’s primary objective was to define the borders between a healthy tissue and tumor. It helps to keep the healthy tissue after the treatment and thus improves overall system performance.
Table Of Content:
1 Market Overview
2 Manufacturers Profiles
3 Global Market Competition, by Players
4 Global Market Size by Regions
5 North America Revenue by Countries
6 Europe Revenue by Countries
7 Asia-Pacific Revenue by Countries
8 South America Revenue by Countries
9 Middle East and Africa Revenue by Countries
10 Global Market Segment by Type
11 Global Market Segment by Application
12 Global Market Size Forecast (2019-2024)
13 Research Findings and Conclusion
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)